178 related articles for article (PubMed ID: 28800321)
21. Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.
Zhu L; Dong C; Cao Y; Fang X; Zhong C; Li D; Yuan Y
PLoS One; 2016; 11(5):e0154795. PubMed ID: 27138801
[TBL] [Abstract][Full Text] [Related]
22. The impact of kidney function on colorectal cancer patients with localized and regional diseases: An observational study from Taiwan.
Chiang SF; Chen JS; Tang R; Yeh CY; Hsieh PS; Tsai WS; You JF; Hung HY; Lai CC; Lin JR; Chiang JM
Indian J Cancer; 2019; 56(3):241-247. PubMed ID: 31389388
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
24. Early and late results of adjuvant treatment in colorectal cancer. The experience of the Emergency County hospital Alba Iulia-Romania.
Curca RO
J BUON; 2009; 14(2):219-24. PubMed ID: 19650169
[TBL] [Abstract][Full Text] [Related]
25. Survival impact of surgical resection of primary tumor in patients with stage IV colorectal cancer: results from a large population-based cohort study.
Ahmed S; Leis A; Fields A; Chandra-Kanthan S; Haider K; Alvi R; Reeder B; Pahwa P
Cancer; 2014 Mar; 120(5):683-91. PubMed ID: 24222180
[TBL] [Abstract][Full Text] [Related]
26. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
27. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
31. Effect and safety of intraoperative intraperitoneal chemotherapy on patients suffering from colorectal cancer.
Shang A; Wang S; Yang Y; Li L; Zhao Z; Li D; Guo Y; Wang M
World J Surg Oncol; 2021 Mar; 19(1):84. PubMed ID: 33752702
[TBL] [Abstract][Full Text] [Related]
32. Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.
Sgouros J; Aravantinos G; Kouvatseas G; Rapti A; Stamoulis G; Bisvikis A; Res H; Samantas E
J Gastrointest Cancer; 2015 Dec; 46(4):343-9. PubMed ID: 26143067
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study.
Arakawa K; Kawai K; Tanaka T; Hata K; Sugihara K; Nozawa H
Colorectal Dis; 2018 Jul; 20(7):O162-O172. PubMed ID: 29752849
[TBL] [Abstract][Full Text] [Related]
34. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
35. Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer.
Kishiki T; Masaki T; Matsuoka H; Kobayashi T; Suzuki Y; Abe N; Mori T; Sugiyama M
Am J Surg; 2013 Aug; 206(2):234-40. PubMed ID: 23827511
[TBL] [Abstract][Full Text] [Related]
36. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
[TBL] [Abstract][Full Text] [Related]
37. The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer.
Song Y; Yang Y; Gao P; Chen X; Yu D; Xu Y; Zhao J; Wang Z
BMC Cancer; 2017 Nov; 17(1):744. PubMed ID: 29126400
[TBL] [Abstract][Full Text] [Related]
38. Dynamic evaluation of mesenchymal circulating tumor cells in patients with colorectal cancer: Clinical associations and prognostic value.
Shi DD; Yang CG; Han S; Wang SY; Xiong B
Oncol Rep; 2020 Aug; 44(2):757-767. PubMed ID: 32627039
[TBL] [Abstract][Full Text] [Related]
39. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
